Akos

Akos is a first-in-class small-molecule inhibitor designed to target the tumor microenvironment by reprogramming metastatic cancer-associated fibroblasts (mCAF). It selectively blocks the formation and signaling of a specific proteoglycan-modified receptor in mCAFs, which is a key orchestrator of extracellular matrix remodeling, epithelial-mesenchymal transition (EMT), and metastatic dissemination. By disrupting the crosstalk between the stroma and tumor cells, Akos has demonstrated the ability to significantly reduce tumor volume and completely abrogate spontaneous metastasis in preclinical models of prostate, breast, colorectal, and pancreatic cancers. Mechanistic studies indicate that Akos selectively targets the stromal receptor without affecting other proteoglycans, leading to the downregulation of pro-migratory and invasive signaling pathways.